484 related articles for article (PubMed ID: 33796404)
1. Bromodomain protein BRD4 is an epigenetic activator of B7-H6 expression in acute myeloid leukemia.
Baragaño Raneros A; Rodriguez RM; Bernardo Flórez A; Palomo P; Colado E; Minguela A; Suárez Álvarez B; López-Larrea C
Oncoimmunology; 2021 Mar; 10(1):1897294. PubMed ID: 33796404
[TBL] [Abstract][Full Text] [Related]
2. Mimicking an induced self phenotype by coating lymphomas with the NKp30 ligand B7-H6 promotes NK cell cytotoxicity.
Kellner C; Maurer T; Hallack D; Repp R; van de Winkel JG; Parren PW; Valerius T; Humpe A; Gramatzki M; Peipp M
J Immunol; 2012 Nov; 189(10):5037-46. PubMed ID: 23066150
[TBL] [Abstract][Full Text] [Related]
3. All-trans retinoic acid induces leukemia resistance to NK cell cytotoxicity by down-regulating B7-H6 expression via c-Myc signaling.
Cao G; Cheng Y; Zheng X; Wei H; Tian Z; Sun R; Sun H
Cancer Commun (Lond); 2021 Jan; 41(1):51-61. PubMed ID: 34236140
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of the activating NKp30 ligand B7-H6 by HDAC inhibitors impairs tumor cell recognition by NK cells.
Fiegler N; Textor S; Arnold A; Rölle A; Oehme I; Breuhahn K; Moldenhauer G; Witzens-Harig M; Cerwenka A
Blood; 2013 Aug; 122(5):684-93. PubMed ID: 23801635
[TBL] [Abstract][Full Text] [Related]
5. Expression, crystallization and X-ray diffraction analysis of a complex between B7-H6, a tumor cell ligand for the natural cytotoxicity receptor NKp30, and an inhibitory antibody.
Xu X; Li Y; Gauthier L; Chen Q; Vivier E; Mariuzza RA
Acta Crystallogr F Struct Biol Commun; 2015 Jun; 71(Pt 6):697-701. PubMed ID: 26057798
[TBL] [Abstract][Full Text] [Related]
6. Allogeneic and xenogeneic anti-tumor effect of callithrix jacchus natural killer cells is dependent on NKp30 and B7-H6 interaction.
Müller T; Schlahsa L; Zhang HJ; Skaik Y; Eiz-Vesper B; Immenschuh S; Blasczyk R; Figueiredo C
J Biol Regul Homeost Agents; 2014; 28(2):183-93. PubMed ID: 25001651
[TBL] [Abstract][Full Text] [Related]
7. Secreted Ligands of the NK Cell Receptor NKp30: B7-H6 Is in Contrast to BAG6 Only Marginally Released via Extracellular Vesicles.
Ponath V; Hoffmann N; Bergmann L; Mäder C; Alashkar Alhamwe B; Preußer C; Pogge von Strandmann E
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33671836
[TBL] [Abstract][Full Text] [Related]
8. NKP30-B7-H6 Interaction Aggravates Hepatocyte Damage through Up-Regulation of Interleukin-32 Expression in Hepatitis B Virus-Related Acute-On-Chronic Liver Failure.
Zou Y; Bao J; Pan X; Lu Y; Liao S; Wang X; Wang G; Lin D
PLoS One; 2015; 10(8):e0134568. PubMed ID: 26241657
[TBL] [Abstract][Full Text] [Related]
9. BRD4 Inhibitor GNE-987 Exerts Anticancer Effects by Targeting Super-Enhancer-Related Gene LYL1 in Acute Myeloid Leukemia.
Sang X; Zhang Y; Fang F; Gao L; Tao Y; Li X; Zhang Z; Wang J; Tian Y; Li Z; Yao D; Wu Y; Chu X; Zhang K; Ma L; Lu L; Chen Y; Yu J; Zhuo R; Wu S; Zhang Z; Pan J; Hu S
J Immunol Res; 2022; 2022():7912484. PubMed ID: 35958877
[TBL] [Abstract][Full Text] [Related]
10. Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30.
Schlecker E; Fiegler N; Arnold A; Altevogt P; Rose-John S; Moldenhauer G; Sucker A; Paschen A; von Strandmann EP; Textor S; Cerwenka A
Cancer Res; 2014 Jul; 74(13):3429-40. PubMed ID: 24780758
[TBL] [Abstract][Full Text] [Related]
11. Clinical impact of the NKp30/B7-H6 axis in high-risk neuroblastoma patients.
Semeraro M; Rusakiewicz S; Minard-Colin V; Delahaye NF; Enot D; Vély F; Marabelle A; Papoular B; Piperoglou C; Ponzoni M; Perri P; Tchirkov A; Matta J; Lapierre V; Shekarian T; Valsesia-Wittmann S; Commo F; Prada N; Poirier-Colame V; Bressac B; Cotteret S; Brugieres L; Farace F; Chaput N; Kroemer G; Valteau-Couanet D; Zitvogel L
Sci Transl Med; 2015 Apr; 7(283):283ra55. PubMed ID: 25877893
[TBL] [Abstract][Full Text] [Related]
12. Structure of the human activating natural cytotoxicity receptor NKp30 bound to its tumor cell ligand B7-H6.
Li Y; Wang Q; Mariuzza RA
J Exp Med; 2011 Apr; 208(4):703-14. PubMed ID: 21422170
[TBL] [Abstract][Full Text] [Related]
13. Disruption of BRD4 at H3K27Ac-enriched enhancer region correlates with decreased c-Myc expression in Merkel cell carcinoma.
Sengupta D; Kannan A; Kern M; Moreno MA; Vural E; Stack B; Suen JY; Tackett AJ; Gao L
Epigenetics; 2015; 10(6):460-6. PubMed ID: 25941994
[TBL] [Abstract][Full Text] [Related]
14. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia.
Zuber J; Shi J; Wang E; Rappaport AR; Herrmann H; Sison EA; Magoon D; Qi J; Blatt K; Wunderlich M; Taylor MJ; Johns C; Chicas A; Mulloy JC; Kogan SC; Brown P; Valent P; Bradner JE; Lowe SW; Vakoc CR
Nature; 2011 Aug; 478(7370):524-8. PubMed ID: 21814200
[TBL] [Abstract][Full Text] [Related]
15. Targeting Oncogenic Super Enhancers in MYC-Dependent AML Using a Small Molecule Activator of NR4A Nuclear Receptors.
Call SG; Duren RP; Panigrahi AK; Nguyen L; Freire PR; Grimm SL; Coarfa C; Conneely OM
Sci Rep; 2020 Feb; 10(1):2851. PubMed ID: 32071334
[TBL] [Abstract][Full Text] [Related]
16. Structural Insights into the Inhibitory Mechanism of an Antibody against B7-H6, a Stress-Induced Cellular Ligand for the Natural Killer Cell Receptor NKp30.
Xu X; Narni-Mancinelli E; Cantoni C; Li Y; Guia S; Gauthier L; Chen Q; Moretta A; Vély F; Eisenstein E; Rangarajan S; Vivier E; Mariuzza RA
J Mol Biol; 2016 Nov; 428(22):4457-4466. PubMed ID: 27663271
[TBL] [Abstract][Full Text] [Related]
17. B7-H6, an immunoligand for the natural killer cell activating receptor NKp30, reveals inhibitory effects on cell proliferation and migration, but not apoptosis, in cervical cancer derived-cell lines.
Banu N; Riera-Leal A; Haramati J; Ortiz-Lazareno PC; Panikar SS; Bastidas-Ramirez BE; Gutierrez-Silerio GY; Solorzano-Ibarra F; Tellez-Bañuelos MC; Gutierrez-Franco J; Bueno-Topete MR; Pereira-Suarez AL; Del Toro-Arreola S
BMC Cancer; 2020 Nov; 20(1):1083. PubMed ID: 33172426
[TBL] [Abstract][Full Text] [Related]
18. Affinity Maturation of B7-H6 Translates into Enhanced NK Cell-Mediated Tumor Cell Lysis and Improved Proinflammatory Cytokine Release of Bispecific Immunoligands via NKp30 Engagement.
Pekar L; Klausz K; Busch M; Valldorf B; Kolmar H; Wesch D; Oberg HH; Krohn S; Boje AS; Gehlert CL; Toleikis L; Krah S; Gupta T; Rabinovich B; Zielonka S; Peipp M
J Immunol; 2021 Jan; 206(1):225-236. PubMed ID: 33268483
[TBL] [Abstract][Full Text] [Related]
19. The proto-oncogene Myc drives expression of the NK cell-activating NKp30 ligand B7-H6 in tumor cells.
Textor S; Bossler F; Henrich KO; Gartlgruber M; Pollmann J; Fiegler N; Arnold A; Westermann F; Waldburger N; Breuhahn K; Golfier S; Witzens-Harig M; Cerwenka A
Oncoimmunology; 2016 Jul; 5(7):e1116674. PubMed ID: 27622013
[TBL] [Abstract][Full Text] [Related]
20. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myelogenous leukemia cells.
Fiskus W; Sharma S; Qi J; Valenta JA; Schaub LJ; Shah B; Peth K; Portier BP; Rodriguez M; Devaraj SG; Zhan M; Sheng J; Iyer SP; Bradner JE; Bhalla KN
Mol Cancer Ther; 2014 May; 13(5):1142-54. PubMed ID: 24435446
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
